Our name combines these ideas. As the world’s #1 drug development, delivery and supply partner with over 80 years of experience, we are the catalyst for your success. We have helped thousands of innovators by optimizing and manufacturing thousands of pharmaceutical, biologic, consumer health and beauty products utilizing our superior and innovative drug delivery technologies to improve their value to patients and consumers. And Catalent’s “Patient First” culture puts patients at the center of our work to ensure the safety, reliable supply and optimal performance of our products.

Catalent is a vibrant growing community of 10,000+ global employees with the passion to unlock the potential of your product. Founded in 2007 as Catalent, our legacy of drug development goes much deeper, incorporating the inventions and innovations which have transformed the pharmaceutical industry. On July 30, 2014 Catalent announced its initial public offering and became a publicly traded on the New York Stock Exchange under the ticker symbol CTLT.

From early development to clinical supply and commercial manufacturing, our 30+ global site teams support you through all phases of development, delivery, and supply, accelerating your product’s path to market in segments such as pharmaceuticals, biologics, consumer health and beauty, and animal health utilizing our superior drug delivery technologies to improve therapeutic and product value to patients and consumers.

Our Eberbach, Germany facility is our biggest softgel development and manufacturing facility in Europe with capacity of 12.8 billion softgel capsules per year. It features integrated softgel manufacturing services including coating and packaging simplify supply chain management and deliver products faster to market. The facility can handle highly potent and cytotoxic compound with our self-contained, separated cytotoxic suite. Within the Catalent network, we offer a broad range of integrated formulation and analytical services to solve your most difficult development and manufacturing challenges.